The mean CPK level before starting PCSK9 inhibitor therapy was 1028.6 ± 749.43 IU/L, while the most recent measurement after myositis treatment and the use of PCSK9 inhibitors was within normal limits (135 IU/L). Here, PCSK9 is linked to myositis disease.